May 28, 2026
Interim Leadership Is Surging in Life Sciences. Here's Why.
Colleen Cremen, Managing Director, Alder Brooks
Demand for interim executive leaders hassurged 310% since 2020.
That's not a trend. That's a structural shift. And life sciences is feeling it directly.
What's driving this
Life sciences companies aren't operating in steady-state environments anymore. Regulatory complexity is increasing. Scientific innovation cycles are accelerating. AI is reshaping R&D and operations faster than most hiring timelines can keep up with.
Transformation used to be episodic. Now it's continuous. And the leaders who can step in mid-stream and execute? Those folks are in high demand.
At the same time, 83% of pharmaceutical and life sciences companies report difficulty finding skilled talent. Executive turnover is rising across the C-suite. Retained searches still take months. Business inflection points don't wait.
Something had to give.
The supply side shifted too
This isn't just a demand story. More senior executives are actively choosing independent careers. Twenty+ years of experience, and they're choosing flexibility and variety over another full-time role. What used to look like a niche path is now a scaled talent market.
At Alder Brooks, we have spoken with many leaders who received multiple permanent offers and chose interim or fractional roles. Not because they had to. Because they wanted to.
Why boards are paying attention
Permanent executive hires are expensive. And increasingly risky. Interim leadership offers immediate execution, lower long-term commitment, and real performance validation before any permanent decision is made. Conversion from interim to permanent is rising because companies are seeing it work in real time.
That's not a consolation prize. That's a smarter hiring model.
What's at stake in this industry specifically
In life sciences, timing is everything. A delayed hire isn't just inconvenient. It can mean missed milestones, delayed filings, lost market opportunity, and reduced investor confidence.
Companies that treat a leadership gap as something to wait out are taking on more risk than they realize.
The bottom line
Interim leadership isn't replacing permanent hiring. It's redefining it.
At Alder Brooks, we help life sciences and healthcare companies put experienced leaders in place when the business needs them, not when a search process finishes.
The question isn't whether you need experienced leadership. It's whether you can afford to wait.
Alder Brooks: Save Time. Grow.™
Sources
1. HR Business Partners, Adapting to the Rise of Fractional HR Services in 2026, citing Heidrick & Struggles data. https://www.hrbponline.com/post/adapting-to-the-rise-of-fractional-hr-services-in-2026
2. Deloitte, 2023 survey on pharmaceutical and life sciences talent, as reported by Pharmaceutical Executive. https://www.pharmexec.com/view/three-ways-to-close-talent-gap
